NYSE:GILD 23 January 2026

Gilead stock jumps again as Trodelvy-Keytruda breast cancer data hit NEJM

Gilead Sciences shares rose 3.5% to $135.73 Friday, hitting new highs after Phase 3 trial data showed its Trodelvy-Keytruda combo cut the risk of disease progression or death by 35% in metastatic triple-negative breast cancer. Gilead has filed for expanded approval in the U.S. and Europe. Volume reached 8.8 million shares. A Form 144 filing showed executive Deborah Telman plans to sell up to 29,215 shares.

23 January 2026

Biotechnology·NYSE:GILD·NYSE:JNJ·NYSE:MRK·Pharmaceutical News·Stock Market

Smiths Group Shares Fall 6% Despite Strategic Sales and Capital Returns
March 20, 2026, 7:37 AM EDT. Shares of Smiths Group (LSE:SMIN) dropped 5.9% to 2,222p following mixed half-year results and slightly lowered full-year guidance. The company saw organic revenue growth of 4% and a 7.2% rise in headline operating profit to £248 million, with margins improving 50 basis points to 17.2%. However, statutory profits fell sharply due to one-off charges, causing a 17.4% drop in earnings per share. CEO Roland Carter highlighted the sale of Smiths Detection and Smiths Interconnect as transformational, alongside a £1.5 billion planned shareholder return through 2027. Analysts noted investor disappointment over modest revenue growth and trimmed guidance, despite a 5.4% dividend increase. Long-term outlook remains positive with disposals, acquisitions, and capital returns aiming for mid-term 5-7% organic growth and 21-23% margins, seen as a potential buying opportunity by some market watchers.